Rating Change
UBS analysts initiated coverage on Mineralys Therapeutics, Inc. (NASDAQ:MLYS) with a rating of Neutral on October 12, 2026.
new coverageNASDAQ:MLYS
UBS Initiates Coverage on Mineralys Therapeutics, Inc. (MLYS) with Neutral
UBS analysts initiated coverage on Mineralys Therapeutics, Inc. (NASDAQ:MLYS) with a rating of Neutral on October 12, 2026.
At publication ·
What changed
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) · new coverage
- Firm
- UBS
- Rating
- Neutral
- Price at event
- $22.24
- Market capitalization
- $2.4B
At a glance
Key takeaways
- UBS initiated coverage on Mineralys Therapeutics (MLYS) with a Neutral rating on October 12, 2026, contrasting with 9 Buy ratings among the 10 most recent analyst opinions.
Market Context
Mineralys Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $22.24 with a market capitalization of $2.4B. The stock has declined 37.7% over the past 52 weeks.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Mineralys Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Mineralys Therapeutics, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 12, 2026 | UBS | Neutral | N/A |
| Oct 12, 2026 | HC Wainwright & Co. | Buy | N/A |
| Apr 27, 2026 | TD Cowen | Buy | N/A |
| Mar 13, 2026 | B of A Securities | Buy | N/A |
| Dec 19, 2025 | Stifel | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View MLYS Stock Page
Frequently Asked Questions
What does the Neutral rating mean for MLYS?
A rating of Neutral from UBS reflects the analyst's outlook on Mineralys Therapeutics, Inc. (NASDAQ:MLYS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MLYS forecast page.